{
    "nct_id": "NCT05119855",
    "official_title": "A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age",
    "inclusion_criteria": "* Has not yet had coitarche and does not plan on becoming sexually active during the vaccination period\n* Participant or participant's legally acceptable representative can read, understand, and complete the electronic vaccination report card (eVRC).\nHealthy volunteers allowed\nMust have minimum age of 9 Years\nMust have maximum age of 11 Years",
    "exclusion_criteria": "* Known allergy to any vaccine component\n* History of severe allergic reaction that required medical intervention\n* Thrombocytopenia or any coagulation disorder\n* Has a history of myocarditis or pericarditis\n* Has a history of a clinical or microbiological diagnosis of COVID-19 â‰¤90 days prior to Day 1 visit or history of multisystem inflammatory syndrome in children (MIS-C) at any time prior to Day 1 visit\n* Females only: participant is pregnant\n* Currently immunocompromised, or been diagnosed with immunodeficiency\n* Had a splenectomy\n* Receiving or has received immunosuppressive therapies within the last year\n* Received any immunoglobulin product or blood-derived product within 3 months\n* Received a marketed HPV vaccine or has participated in an HPV vaccine clinical trial",
    "miscellaneous_criteria": ""
}